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ABSTRACT
The Abernethy malformation consists of a congenital extrahepatic portosystemic shunt and is believed to be extremely
rare in humans. The potential implications of abnormal portovenous shunting and decreased hepatic portal flow are
numerous and potentially serious. Although congenital extrahepatic portosystemic shunts are increasingly suspected and
diagnosed in specialized centres, much of their clinical presentation and natural history is not fully understood. Symptoms
of portosystemic shunt are mainly caused by increased levels of ammonia, which lead to signs of encephalopathy.
Therapeutic options depend on the type of shunt and its clinical course, so the classification of the congenital
portosystemic shunt is a key finding in these patients.
INTRODUCTION
A portosystemic shunt is defined by the establishment of
an atypical connection between the portal vascular system
and the systemic circulation. Hence, blood that derives
from the abdominal organs, and therefore should follow to
the liver by means of the portal vein, is improperly shunted
to the systemic circulation. As a consequence, toxins
absorbed at the intestinal wall bypass the liver and proceed
straight into the systemic circulation. Portosystemic shunts
can be congenital or acquired. There are two major catego-
ries of congenital shunts, extrahepatic and intrahepatic.
The Abernethy malformation, as the name suggests, was
first described by Abernethy and consists of a congenital
extrahepatic portosystemic shunt (CEPS).1,2 This condition
results from persistence of embryonic vessels and is
extremely rare in humans. It comprises a group of vascular
anomalies of the splanchnic venous system and is charac-
terized by the presence of portomesenteric venous blood
draining directly into systemic veins. There are two main
types of Abernethy malformations that have been
described3: Type I (end-to-side shunt) and Type II (side-
to-side) shunts. In Type I, there is complete diversion of
portal circulation into the systemic blood, apparently with
absent intrahepatic portal branches. These Type I shunts
are further divided into those in which the splenic vein
(SV) and superior mesenteric vein (SMV) drain separately
into a systemic vein (Type Ia), and those in which the SV
and SMV drain together, after joining to form an abnor-
mally small portal trunk (Type Ib). In Type II shunts, the
intrahepatic portal vein is intact but hypoplastic, and some
of the portal blood is diverted into a systemic vein (usually
the inferior vena cava) through a side-to-side extrahepatic
communication. In this type, a variable degree of portal
perfusion to the liver remains because there are patent
intrahepatic portal veins.
The number of CEPS diagnoses have been increasing in
recent years owing to advances in imaging techniques, foe-
tal diagnosis and neonatal mass screening.4,5
CASE PRESENTATION
A 55-year-old male was admitted to our hospital with clini-
cal evidence of encephalopathy. Physical examination
revealed mild jaundice. The patient’s medical history
included hypertension, diabetes mellitus, knee arthrosis
and resection of a basal cell carcinoma in the nose. The
patient was also considered to have hepatic disease, proba-
bly related to alcohol consumption. There was a history of
alcohol abuse, but the patient referred abstinence from
alcohol consumption for the past 6 years.
Liver function testing revealed normal transaminase levels
and a total bilirubin level of 2.16 mg dl–1 (normal, 0.20–
1.20 mg dl–1). Serum total protein and albumin were
within normal ranges. On haematological studies, no
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anaemia or coagulopathy was observed. Serum ammonia level
was elevated, at 174 mmol l–1. Serologic markers for hepatitis B
and C were negative; a-fetoprotein was also negative. Labora-
tory findings on admission are summarized in Table 1.
Abdominal ultrasonography revealed a diffuse heterogenic
echostructure in the liver (Figure 1a, b). Abdominal CT showed
the presence of an abnormal short portal vein, with systemic
drainage into the inferior cava vein below the liver, and the supe-
rior mesenteric vein and splenic vein draining into the abnormal
portal vein (Figure 2) (video 1). The venous phase and multipla-
nar curve reformatted images better depicted this short, dilated
shunt vessel (abnormal portal vein) after the confluence of the
superior mesenteric vein and splenic vein, and the inferior vena
cava (Figure 3). Various nodular hepatic lesions could also be
observed, compatible with vascular shunts and regenerative nod-
ules, with the larger nodule presenting a size of 13 mm in diame-
ter. The benign nature of these nodular lesions was confirmed
by their stability through at least 7 years. Furthermore, a dilated
and tortuous hepatic artery was also detected
(Figure 4) (video 2). Although several imaging examinations
had been performed during this 7-year time frame, the vascular
malformation had not been diagnosed so far. MRI shows the
presence of the shunt with similar findings (Figure 5) (video 3).
During a 6-day period of admission in the internal medicine
department, the patient received conservative treatment with
enema, lactulose, restricted protein intake and branched-chain
amino acids. The serum ammonia level improved to 50–60
mmol l–1, measured at the day of discharge.
DIAGNOSIS
According to Ohwada et al6 the diagnostic criteria for congenital
portosystemic shunt (CPS) include the following:
1. no hypersplenism or portal hypertension
2. no remarkable microscopic changes in liver specimens,
such as those of hepatitis, cirrhosis, or idiopathic portal
hypertension
3. hypoplastic portal vein with no arterioportal fistula
4. no previous history of abdominal surgery or
inflammation.
In the paediatric population, shunts have been detected most
often incidentally, usually in the investigation of associated liver
dysfunction or cardiac anomalies. The clinical significance of
CPS is based specially on these associations, particularly congen-
ital heart defects and nodular liver lesions. However, the clinical
diagnosis can be more challenging in older patients, especially in
those with coexisting chronic liver disease (much more
common) and no early diagnosis of CEPS. Some cases have been
misdiagnosed as psychiatric diseases and, subsequently, patients
have been hospitalized in psychiatric departments or
geriatric institutions.7
Shunts can occasionally be detected as the cause of encephalopa-
thy, secondary to chronic hyperammonemia. In CEPS, however,
the typically secondary signs of portal venous hypertension such
as ascites, varices or splenomegaly are usually absent.8,9
For all these reasons, and owing to the fact that the clinical pre-
sentations of CEPS can vary extensively, other manifestations
cannot be neglected, namely encephalopathy, particularly when
diagnosed in older people, as in the case presented in our
report.
Table 1. Laboratory data on admission.
Haematology
WBC 4.4 x 109 l–1
RBC 5.06 x 1012 l–1
Hb 16.8 g dl–1
Ht 46.4%










TP 6.9 g dl–1
Alb 3.9 g dl–1
T-Bil 2.16 mg dl–1
D-Bil 0.8 mg dl–1
AST 29 IUl–1
ALT 32 IU l–1
LDH 296 IU l–1
g-GTP 23 IU l–1
ALP 59 IU l–1
BUN 28 mg dl
Cr 0.7 mg dl–1
CRP 3.5 mg dl–1
AFP 2 ng dl–1
NH3 174.6 mmol l
–1
g-GTP, gamma-glutamyl transferase; AFP, alpha-fetoprotein;
Alb, albumin; ALP, alkaline phosphatase; ALT, alanine transami-
nase; APTT, activated partial thromboplastin time; AST, aspar-
tate transaminase; BUN, blood urea nitrogen; Cr, creatinine;
CRP, C-reactive protein; D-Bil, direct bilirubin; Hb, haemoglobin;
HbsAg, Hepatitis B virus surface antigen; HbsAb, Hepatitis B
surface antibody; HCV, Hepatitis C virus; Ht, haematocrit; INR,
international normalized ratio; LDH, lactate dehydrogenase;
NH3, ammonia; Plt, platelets; PT, prothrombin time; RBC, red
blood cell; T-Bil, total bilirubin; TP, total protein; WBC, white
blood cell.
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Classification
In addition to the most often used anatomical classification,
Kobayashi et al5 reviewed 136 cases of CEPS and proposed a
classification according to the drainage vessel of the portosyste-
mic shunts, which can be viewed as a clinical classification of
CEPS. Portal blood flow is then classified by the authors as type
A when it is directed into the inferior vena cava (IVC), type B
into the renal vein and type C into the iliac vein via the inferior
mesenteric vein. According to the authors, this portosystemic
shunt classification is more useful to discriminate between the
incidences of cardiac anomalies, gastrointestinal bleeding and
also prognosis. In this “clinical classification,” the prevalence of
cardiac anomalies in patients presenting with type A portal
blood flow was slightly higher when compared with patients
Figure 1. Abdominal ultrasound revealed a normal-sized liver, with a diffusely heterogeneous echostructure suggesting chronic liver
disease (a and b). On CT (c and d) the liver is slightly dysmorphic. There is a nodular liver lesion in the right lobe, with CT enhance-
ment pattern in the arterial (c) and portal (d) phases suggesting a benign vascular shunt (arrow in b), which is stable on comparing
with multiple previous examinations (not shown).
Figure 2. Contrast-enhanced abdominal CT scan. Coronal images showed the presence of an abnormal short portal vein, with a sys-
temic drainage in the inferior cava vein (a), and the superior mesenteric vein and splenic vein draining in the abnormal portal vein (b
and c), as depicted by the arrows.
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presenting with other shunt types. However, the presence of
lower gastrointestinal bleeding was a considerably more com-
mon side-effect in type C patients.
Blanc et al10 proposed another classification based on the caval
ending of the shunt and CEPS, considering it a useful
classification for surgery. In a recent report from 2015 by
Kanazawa et al,11 a different classification was put forward based
on the visualization of the architecture of the intrahepatic portal
system. Use of recent techniques in interventional radiology,
specifically the shunt occlusion test, allowed them to visualize
the intrahepatic portal rami, even in patients previously catego-
rized with absent intrahepatic portal branches (Type I). A total
of 18 children with congenital portosystemic shunts who under-
went angiography with a shunt occlusion test were classified on
the basis of the severity of the hypoplasia of the intrahepatic por-
tal system. According to these authors, it can be useful and can
better explain the pathophysiological characteristics of the con-
genital portosystemic shunt and also play a complementary role
in the therapeutic approach and management.
It had been previously stated by Barsky et al that it is highly
likely that Type I patients (according to Morgan’s classification),
evaluated with other imaging methods, have intrahepatic portal
system visualized by angiography under shunt occlusion.12 In
fact, in their report, Kanazawa et al11 demonstrated that almost
every case diagnosed with CPS Type I showed visible intrahe-
patic portal system with the shunt occlusion test. CPS was classi-
fied into three types depending on the severity of the hypoplasia
of intrahepatic portal system: mild type; moderate type; and
severe type. The radiological balloon occlusion test found that a
hypoplastic portal system existed in cases with Type I CPS
(Morgan’s classification), which had previously been considered
to require liver transplantation. A correlation was also estab-
lished between these differences and the histopathological find-
ings, where the number of portal triads was found to be similar
in the mild, moderate, and severe types. The main disparities,
however, occurred in the size of the portal triads, which were
significantly different in each type. Crescent-shaped portal stric-
tures in a normal-sized portal triad were usually seen in the mild
and moderate types. On the other hand, the area of the portal
triad was small and the portal vein was not or rarely found in
the severe type, suggesting that the intrahepatic portal vascular
bed could not accept a proper portal inflow in the severe type, at
least immediately after shunt closure.
DISCUSSION
Type B hepatic encephalopathy describes encephalopathy asso-
ciated with portal-systemic bypass and no intrinsic
Figure 3. Multiplanar curved reformatted CT images better depicted the short abnormal portal vein draining in the inferior vena
cava (a and b).
Figure 4. Axial CT images acquired during the arterial phase show a dilated (circle in a) and tortuous hepatic artery (arrows in b).
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hepatocellular disease, according to the consensus group at the
11th World Congress of Gastroenterology, where a standardized
nomenclature for hepatic encephalopathy was proposed.13,14
The major responsible for symptoms of portosystemic encepha-
lopathy is ammonia from the digestive system or elsewhere,
which is usually metabolized by the liver in normal conditions,
but can lead to signs of encephalopathy when accumulates in the
body above a limit threshold value. Owing to portosystemic
shunting, whether congenital or not, ammonia enters the sys-
temic circulation and reaches the brain, being toxic to both
astrocytes and neurons.15 Children rarely present with psychiat-
ric manifestations, but hepatic encephalopathy is rare in infants
and children.9 Nevertheless, clinical encephalopathy can ulti-
mately result in cognitive disorders and mental retardation, and
is considered an absolute indication for treatment in children.
Furthermore, a helpful predictor used in screening of CEPS in
neonates is elevated levels of galactose,16 another toxic metabo-
lite that can bypass the liver.
Different studies report different percentages of patients with
encephalopathy associated with congenital shunts, mainly
due to the distinct age of the patients studied. In the review
by Kobayashi et al,5 18 cases of CEPS (13.2%) were identi-
fied as having portosystemic encephalopathy. In their review,
despite the fact that prevalence of portosystemic encephalop-
athy was higher among type A and type B patients and was
very rare among type C patients, there were no statistically
significant differences between the groups, both in anatomi-
cal and clinical classifications. In a series of 97 patients with
extrahepatic obstruction of the portal vein, Webb et al8
reported clinical and electroencephalographic evidence of
portosystemic encephalopathy in 27 (35.5%) cases. However,
in this review the patients were initially diagnosed with
symptoms of portal hypertension. In fact, Morgan et al3
already considered that these malformations would probably
go unnoticed in most patients if it were not for its frequent
association with the more clinically significant liver and
heart anomalies. In initial studies, patients were thought to
present with Type II shunts typically at middle or late-mid-
dle age. Murray et al,17 in turn, contradicted the previously
held belief that Type II shunts are typically diagnosed in
older children and adults, since they found a younger
median age for Type II (2 years versus 10 years for Type I).
Studies with larger cohorts are needed to reach a more
detailed evaluation.
Despite the different opinions, the initial symptom can often be
encephalopathy of unknown cause, with the vascular anomaly
detected during investigation, as in the case of our patient. One
of the problems for diagnosis and management is that both clini-
cians and radiologists are generally not sensitized to or aware of
this diagnosis and cases with subtle presentations can be
extremely challenging. A hallmark of this clinical condition is
the elevated ammonia levels. Owing to diminished tolerance of
the ageing brain to high ammonia levels, as age progresses it is
believed that these patients can become, at some point, symp-
tomatic.18,19 Furthermore, the nature of symptoms of portosys-
temic encephalopathy associated with congenital portosystemic
venous shunts depends on the shunt ratio and patient age.
Uchino el al20 reported that a shunt ratio superior to 60%
(determined by portal scintigraphy) was a predisposition for
portosystemic encephalopathy in patients where congenital por-
tosystemic venous shunts were present (including patent ductus
venosus).21,22
Kamiya et al,23 in a case report of a patient with congenital
absence of the portal vein, proposed that alterations in bacterial
intestinal flora, specifically the number of urease-producing
microorganisms, could induce a marked decrease in ammonia
concentration, urease activity and pH of the faeces, which, in
turn, might provide a homeostatic mechanism for maintaining
liver function.
Congenital portosystemic venous shunts can be classified by
different systems, but the most commonly used is the anatom-
ical classification described by Morgan and Superina,3 dividing
it into intrahepatic and extrahepatic (CEPS), according to the
presence or absence of the intrahepatic portal vein. In CEPS,
the anastomoses between the portomesenteric vasculature and
a systemic vein are observed before division of the portal vein
in the hepatic hilum. The draining systemic vessel can vary,
and it can include the renal, iliac, azygos vein or the right
atrium, but the most common is the inferior vena cava
(portocaval shunt).17 While Type I malformation is
Figure 5. MR images show the presence of the shunt with the inferior vena cava (arrows in b), and abnormal portal vein (circle in a).
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predominantly described in females, in Type II there is no
gender predilection in its prevalence. In a review study of 61
cases, Murray et al found a significant female preponderance
(74%) in Type I CEPS, but female preponderance was not sig-
nificant (54%) in Type II. However, they affirmed that given
the likelihood that some cases of Type II CEPS have been
misclassified as Type I, the true gender incidence for each
type cannot be unquestionably established.17
The major challenge both in terms of diagnosis and treatment
choice, as exposed in our case report, is in adults that present
with long-term chronic hyperammonemia and subclinical
encephalopathy. An even more difficult case involves patients
that have moderate to high levels of alcohol consumption. In
these cases, the clinicians and even radiologists usually do not
include a congenital malformation in their differential diagnosis.
Furthermore, the anomaly can go completely unrecognized if
abdominal imaging examinations are not requested.
Our report exemplifies one of these cases, and our patient pre-
sented with a Type Ib shunt (the SMV and SV join to form a
short extrahepatic portal vein, which drains into the inferior
vena cava).
Recognized associations with Abernethy malformations, apart
from hepatic encephalopathy, are hepatic mass lesions, includ-
ing focal nodular hyperplasia, hepatocellular carcinoma and
hepatoblastoma, thought to be related owing to the absence of
the portal vein. Other congenital abnormalities particularly asso-
ciated with Type I shunts are biliary atresia and polysplenia.24,25
None of these last referred conditions were diagnosed in
our patient.
Embryogenesis
Development of congenital portosystemic anastomoses can be
explained by understanding the origin of their embryological
precursors, which have connections that failed to involute
between the 4th and 10th weeks of foetal gestation. Embryologi-
cally, the anterior and posterior cardinal veins give rise to the
systemic veins, which appear as intraembryonic structures. The
portal venous system, however, derives from the extraembryonic
vitelline and umbilical veins, through an extremely complex pro-
cess over the course of the first trimester. Aberrations in this
process may result in anatomical variations within the portal
system. The complicated development of the vena cava, its close
relationship with the development of the vitelline veins and the
abnormal development of these vessels during this stage may
explain the occurrence of the rare congenital extrahepatic
portosystemic anastomoses.24,26
Treatment
Therapeutic options depend on the type of shunt and its clinical
course, so the classification of the CPS is a key finding in these
patients, since it will guide the treatment and determine the cor-
rect management. The presence of major complications, such as
hepatopulmonary shunt and portopulmonary hypertension, is
usually considered an absolute indication for treatment, even
when these conditions are mild.27,28
Classically, Type I patients are referred for liver transplanta-
tion, whereas Type II shunts are amenable to endovascular
treatment.29–31 The capacity of the hypoplastic portal system
to accommodate increased blood flow is a prerequisite for a
possible effective endovascular repair. This is usually accom-
plished by a preprocedure biopsy, which must demonstrate an
intact portal intrahepatic system. Multiple studies have shown
the liver capacity to reexpand or develop new portal veins fol-
lowing shunt closure.11,32–34 The endovascular closure can be
done in a single-stage procedure30 or using a multistage
occlusion technique.34,35 In the last case, a liver biopsy previ-
ous to the procedure is usually mandatory. Regarding the best
choice between single and multistage procedures, Franchi-
Abella et al27 proposed an algorithm based on a cutoff level
of 32 mmHg for the portal vein pressure under shunt occlu-
sion. Franchi-Abella et al27 reported that shunt closure should
always be performed when complications are present, with
the exception of those resolving spontaneously.36 They sug-
gested that even when clinical manifestations are not mean-
ingful, the procedure is still recommended when the patient is
able to tolerate, because the treatment can be ineffective if
performed after important complication occurs. Noteworthy,
as previously reported, once patients begin to develop severe
shunting, the shunt ratio can quickly increase.37
Another aspect of the management is the optimal timing for
treatment, for which additional studies are required. Kanazawa
et al11 also consider that because shunt vessel can expand with
advancing age closure of the shunt would be technically harder
as the patient gets older. Currently, there are no formal indica-
tions for the time of treatment, and therefore, in the majority of
the studies published, regarding concerns about paediatric
patients, early radical treatments are advised to avoid the devel-
opment of clinical manifestations related to portosystemic
shunt. To our knowledge, patients diagnosed in adulthood,
owing to the limited number of cases, have even lesser
reported indications.4,38–40
In cases of older patients with chronic hyperammonemia and
subclinical encephalopathy, the option between closure of the
shunt and control with medical therapies remains controver-
sial.32,33,36,38,41 Medical management of hepatic encephalopa-
thy with no associated liver disease is usually similar to the
treatment of hepatic encephalopathy seen in cirrhotic patients
and includes lactulose or non-absorbable oral antibiotics.7
However, the necessity for early closure of the shunt and its
efficiency in cases where chronic hyperammonemia, and
hence subclinical encephalopathy, is controlled with medical
therapies need more in-depth studies. This is due to fact that
the long-term prognosis of each therapeutic method is cur-
rently unclear.20,42 Some recent studies report significant
recurrence rates of hepatic encephalopathy after embolization
of portosystemic shunts.43,44 It seems, however, that emboliza-
tion of portosystemic shunts may be more effective in patients
without underlying cirrhosis.38,39,45
The patient described in this case report received conservative
treatment with enema, lactulose and restricted protein intake.
The symptoms progressively improved, and he was discharged
after 1 week of admission. The treatment and clinical outcome
were established mainly according to improvement in laboratory
levels of ammonia. He had had previous similar hospital admis-
sions, managed with a similar approach.
BJR|case reports Mesquita et al
6 of 8 birpublications.org/bjrcr BJR Case Rep;3:20170054
LEARNING POINTS
1. Congenital portosystemic shunts are rare vascular
anomalies that can cause encephalopathy in the absence
of cirrhotic liver disease, only detected in the
adulthood.
2. Initial recognition of the presence of non-cirrhotic low-
grade/subclinical encephalopathy can be very difficult
and the suspicion may arise by the presence of otherwise
unexplained signs and symptoms, such as occasional
hypoglycaemia.
3. The diagnosis of congenital portosystemic shunts in
patients with liver disease is even more challenging, and
the occurrence can only be detected by alert clinicians
and/or when alterations suggesting portosystemic
shunting with no abnormalities of liver function tests are
discovered.
4. Abdominal imaging diagnosis plays a central role in these
cases and radiologists should be aware of the possibility in
a suspicious clinical context.
CONSENT
Written informed consent for the case to be published
(including images, case history and data) was obtained from the
patient(s) for publication of this case report, including
accompanying images.
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